Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults
about
Recent progress in West Nile virus diagnosis and vaccinationThe yellow fever 17D virus as a platform for new live attenuated vaccinesWest Nile Virus: biology, transmission, and human infectionA Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple FormulationsPlant-made vaccines against West Nile virus are potent, safe, and economically feasibleEpidemiological and clinical aspects on West Nile virus, a globally emerging pathogen.Immunogenicity of a West Nile virus DIII-cholera toxin A2/B chimera after intranasal deliveryAssurance of neuroattenuation of a live vaccine against West Nile virus: a comprehensive study of neuropathogenesis after infection with chimeric WN/DEN4Δ30 vaccine in comparison to two parental viruses and a surrogate flavivirus reference vaccine.Current trends in West Nile virus vaccine development.The efficacy of inactivated West Nile vaccine (WN-VAX) in mice and monkeysComparison of β-Propiolactone and Formalin Inactivation on Antigenicity and Immune Response of West Nile VirusA hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice.An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibodyA review of vaccine approaches for West Nile virus.TLR3- and MyD88-dependent signaling differentially influences the development of West Nile virus-specific B cell responses in mice following immunization with RepliVAX WN, a single-cycle flavivirus vaccine candidateWest Nile virus state of the art report of MALWEST Project.Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus.West Nile virus infection and immunity.Technologies for the development of West Nile virus vaccines.Current status and future prospects of yellow fever vaccines.An Overview of Current Approaches Toward the Treatment and Prevention of West Nile Virus Infection.Safety and immunogenicity of a chimeric vaccine for West Nile virus in aged subjects.Are we prepared for emerging flaviviruses in Europe? Challenges for vaccination.West nile virus.The Immune Responses of the Animal Hosts of West Nile Virus: A Comparison of Insects, Birds, and Mammals.
P2860
Q21284433-5C92053B-7E94-4376-B56A-E15DE0B619CFQ26865102-954FC575-2847-4184-87B2-26FE3F9EA141Q26865618-617E8157-59B3-47F2-9CCF-B4E951D9B2ABQ27321020-4B150EBA-3FDA-4E72-A7E9-B7BB68F41BE8Q28082778-30846B25-D50C-42E6-980C-C20DAAD26C47Q30250251-D3A8715B-3DA2-4AEB-BC1C-AFE7D52982C1Q33584872-19DD09DE-6461-4594-9649-4D318213CBF1Q33909344-96FAC240-C11A-4D58-BDFC-373D2E6BE341Q34788758-2174677D-58E0-45A4-A2CA-C7DD2617C7BBQ35492767-EF889C18-71B0-41D1-AE49-3FBF7368B80DQ36043444-977287FA-191A-4805-8D85-A1BA55901B15Q36607383-85067D75-3F14-4C36-87B7-B854155DE704Q37123147-6C6CB43E-0AD3-45C3-846E-C6E8FFFF2D80Q37236968-BEAE2642-753D-463B-A843-D7082CA2DA2BQ37254256-FFC64BD5-A9CA-4387-826F-2401769A6707Q37434776-46343495-F9FB-4F6D-9B3C-4BB9BA9491A3Q37666763-553A95B4-8335-4D1B-84C9-4822652B11EAQ38074266-C844FC7C-5CF9-4BEB-BB7D-3BFBFA87368DQ38269151-0B6D54FD-CBFD-47B2-9379-4E341CFCFD3EQ38586294-83A1A49C-5849-47A4-A313-A57650BB14F0Q38866173-449C0E15-FFBB-4178-B283-90296578C9EFQ40324111-C3747EDE-72FC-4E16-AF4A-251BD403C359Q43047253-742601A1-FABF-4E7C-A9CC-FFF33D145813Q51860606-28CC8079-CAE4-4C1D-A702-FECA0B9D25F9Q52880885-82BFD255-1706-4093-BBDB-AEC6A8A6165F
P2860
Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Phase II, randomized, double-b ...... irus vaccine in healthy adults
@ast
Phase II, randomized, double-b ...... irus vaccine in healthy adults
@en
Phase II, randomized, double-b ...... irus vaccine in healthy adults
@nl
type
label
Phase II, randomized, double-b ...... irus vaccine in healthy adults
@ast
Phase II, randomized, double-b ...... irus vaccine in healthy adults
@en
Phase II, randomized, double-b ...... irus vaccine in healthy adults
@nl
prefLabel
Phase II, randomized, double-b ...... irus vaccine in healthy adults
@ast
Phase II, randomized, double-b ...... irus vaccine in healthy adults
@en
Phase II, randomized, double-b ...... irus vaccine in healthy adults
@nl
P2093
P2860
P921
P356
P1476
Phase II, randomized, double-b ...... irus vaccine in healthy adults
@en
P2093
Anne M Gregg
Joan Bevilacqua
Mike Watson
Rex Biedenbender
P2860
P356
10.1093/INFDIS/JIQ003
P407
P577
2011-01-01T00:00:00Z